The Experts below are selected from a list of 87336 Experts worldwide ranked by ideXlab platform

Michael Swash - One of the best experts on this subject based on the ideXlab platform.

H. Norris - One of the best experts on this subject based on the ideXlab platform.

Fang Fang - One of the best experts on this subject based on the ideXlab platform.

  • Lipids, apolipoproteins, and prognosis of Amyotrophic Lateral Sclerosis.
    Neurology, 2020
    Co-Authors: Caroline Ingre, Lin Chen, Yiqiang Zhan, Jet Termorshuizen, Li Yin, Fang Fang
    Abstract:

    Objective To determine whether lipids and apolipoproteins predict prognosis of patients with Amyotrophic Lateral Sclerosis in a cohort study of 99 patients with Amyotrophic Lateral Sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Karolinska University Hospital in Stockholm, Sweden. Methods Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein AI, apolipoprotein B, and lipid ratios were measured at the time of Amyotrophic Lateral Sclerosis diagnosis or shortly thereafter. Death after Amyotrophic Lateral Sclerosis diagnosis was used as the main outcome. The Cox model was used to estimate hazard ratios with 95% confidence intervals of death after Amyotrophic Lateral Sclerosis diagnosis, after controlling for sex, age at diagnosis, site of symptom onset, diagnostic delay, body mass index, Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised score, and progression rate. Results A 1-SD increase of total cholesterol (hazard ratio 0.60, 95% confidence interval 0.41–0.89, p = 0.01), low-density lipoprotein cholesterol (hazard ratio 0.64, 95% confidence interval 0.44–0.92, p = 0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (hazard ratio 0.65, 95% confidence interval 0.46–0.92, p = 0.02), apolipoprotein B (hazard ratio 0.62, 95% confidence interval 0.44–0.88, p = 0.01), or apolipoprotein B/apolipoprotein AI ratio (hazard ratio 0.61, 95% confidence interval 0.43–0.86, p Conclusions Lipids and apolipoproteins are important prognostic indicators for Amyotrophic Lateral Sclerosis and should be monitored at the diagnosis of Amyotrophic Lateral Sclerosis.

  • Lipids, apolipoproteins, and prognosis of Amyotrophic Lateral Sclerosis
    'Ovid Technologies (Wolters Kluwer Health)', 2020
    Co-Authors: Ingre Caroline, Li Yin, Chen Lin, Zhan Yiqiang, Termorshuizen Jet, Fang Fang
    Abstract:

    Objective: To determine whether lipids and apolipoproteins predict prognosis of patients with amyo- trophic Lateral Sclerosis in a cohort study of 99 patients with Amyotrophic Lateral Sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Karolinska University Hospital in Stockholm, Sweden. Methods: Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein AI, apolipoprotein B, and lipid ratios were measured at the time of Amyotrophic Lateral Sclerosis diagnosis or shortly thereafter. Death after Amyotrophic Lateral Sclerosis diagnosis was used as the main outcome. The Cox model was used to estimate hazard ratios with 95% confidence intervals of death after Amyotrophic Lateral Sclerosis diagnosis, after controlling for sex, age at diagnosis, site of symptom onset, diagnostic delay, body mass index, Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised score, and progression rate. Results: A 1-SD increase of total cholesterol (hazard ratio 0.60, 95% confidence interval 0.41–0.89, p = 0.01), low-density lipoprotein cholesterol (hazard ratio 0.64, 95% confidence interval 0.44–0.92, p = 0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (hazard ratio 0.65, 95% confidence interval 0.46–0.92, p = 0.02), apolipoprotein B (hazard ratio 0.62, 95% confidence interval 0.44–0.88, p = 0.01), or apolipoprotein B/apolipoprotein AI ratio (hazard ratio 0.61, 95% confidence interval 0.43–0.86, p < 0.01) was associated with a lower risk of death after Amyotrophic Lateral Sclerosis diagnosis. A dose-response relationship was also noted when these biomarkers were analyzed as categorical variables. Conclusions: Lipids and apolipoproteins are important prognostic indicators for Amyotrophic Lateral Sclerosis and should be monitored at the diagnosis of Amyotrophic Lateral Sclerosis.Swedish Research CouncilEuropean Research CouncilPublishe

Jackie S. De Belleroche - One of the best experts on this subject based on the ideXlab platform.

  • Difficulties in distinguishing sporadic from familial Amyotrophic Lateral Sclerosis
    Annals of neurology, 1996
    Co-Authors: Richard W. Orell, Jj Habgood, Petter Rudge, Russell J.m. Lane, Jackie S. De Belleroche
    Abstract:

    Mutations of the copper/zinc superoxide dismutase (SOD-1) gene are present in around 20% of patients with a family history of Amyotrophic Lateral Sclerosis. The finding of these mutations in patients with sporadic Amyotrophic Lateral Sclerosis is rare. We describe a family with Amyotrophic Lateral Sclerosis associated with the SOD-1 mutation Asp 101 Asn. This mutation was previously described as occurring in a patient with sporadic disease. We discuss the difficulties in defining truly sporadic Amyotrophic Lateral Sclerosis, and the consequent implications on the neurogenetic advice given to other family members.

Nigel Leigh - One of the best experts on this subject based on the ideXlab platform.